 | This articlerelies largely or entirely on asingle source. Relevant discussion may be found on thetalk page. Please helpimprove this article byintroducing citations to additional sources. Find sources: "Rapacuronium bromide" – news ·newspapers ·books ·scholar ·JSTOR(November 2007) |
 Rapacuronium bromide | |
| Clinical data | |
|---|---|
| Other names | [(2S, 3S, 5S, 8R, 9S, 10S, 13S, 14S, 16S, 17S)-3-acetyloxy-10,13-dimethyl-2-(1-piperidyl)-16-(1-prop-2-enyl-3,4,5,6-tetrahydro-2H-pyridin-1-yl)-2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,11 ,12 ,14, 15, 16, 17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoate |
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Not applicable |
| Protein binding | Variable |
| Metabolism | Hydrolyzed to active metabolites CYP system not involved |
| Eliminationhalf-life | 141 minutes (mean) |
| Excretion | Renal and fecal |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.211.226 |
| Chemical and physical data | |
| Formula | C37H61N2O4+ |
| Molar mass | 597.905 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Rapacuronium bromide (brand nameRaplon) is a rapidly acting, non-depolarizingaminosteroidneuromuscular blocker formerly used in modernanaesthesia, to aid and enableendotracheal intubation, which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes inintensive care. As a non-depolarizing agent it did not cause initial stimulation of muscles before weakening them.[1]
Due to risk of fatalbronchospasm it was withdrawn from theUnited States market byOrganon on March 27, 2001, less than 2 years after its FDA approval in 1999.[2]
 | Thisdrug article relating to themusculoskeletal system is astub. You can help Wikipedia byexpanding it. |